MagForce AG is a leader in the area of nanotechnology-based cancer treatment, and the first company worldwide to receive European approval for a medical product using nanoparticles. The novel therapy is available to patients at the NanoTherm® therapy center in Germany at the Charité-Universitätsmedizin Berlin. Additional therapy centers throughout Germany are planned for 2013.
The principle of the therapy is the use of nanoparticles containing ironoxide, which are injected into the tumor in a procedure similar to a biopsy. The patient is then placed in a magnetic field applicator (NanoActivator™), a machine that produces an alternating magnetic field and is very safe for humans. Through this high frequency magnetic field, the nanoparticles begin to oscillate and warmth is produced from directly within the tumor tissue. Depending on the temperature reached and length of treatment, the tumor cells are either directly destroyed or sensitized for the accompanying chemotherapy or radiation.
